Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$2.22 CAD
Change Today +0.02 / 0.91%
Volume 187.3K
PLI On Other Exchanges
Symbol
Exchange
OTC US
Frankfurt
As of 10:12 AM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

prometic life sciences inc (PLI) Snapshot

Open
C$2.20
Previous Close
C$2.20
Day High
C$2.25
Day Low
C$2.19
52 Week High
03/19/15 - C$2.87
52 Week Low
07/28/14 - C$1.13
Market Cap
1.3B
Average Volume 10 Days
1.4M
EPS TTM
C$-0.03
Shares Outstanding
578.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROMETIC LIFE SCIENCES INC (PLI)

Related News

No related news articles were found.

prometic life sciences inc (PLI) Related Businessweek News

No Related Businessweek News Found

prometic life sciences inc (PLI) Details

ProMetic Life Sciences Inc., a biopharmaceutical company, develops bio separations, plasma-derived therapeutics, and small-molecule drugs. The company offers its technologies for large-scale drug purification, drug development, proteomics, and the elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, autoimmune disease/inflammation, and cancer. It operates in two segments, Therapeutics and Protein Technology. The Therapeutics segment’s lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of fibrosis in patients with chronic kidney diseases and certain cancers, and the side effects associated with chemotherapy. This segment is also developing PBI-4419, an anti-fibrotic and anti-inflammatory compound for kidney injury and chronic kidney diseases; and PBI-1402 for the treatment of anemia indications. The Protein Technology segment provides plasma protein purification system, a solution for the extraction and purification of therapeutic proteins from human plasma; bioseparation products based on applications of its patented Mimetic Ligand technology for various biopharmaceutical companies; and prion capture/pathogen removal technology platform that improves the safety profile of blood products and blood-derived therapeutics. The company was formerly known as Innovon Life Sciences Holdings Limited and changed its name to ProMetic Life Sciences Inc. in May 1998. ProMetic Life Sciences Inc. was founded in 1992 and is headquartered in Laval, Canada.

197 Employees
Last Reported Date: 03/31/15
Founded in 1992

prometic life sciences inc (PLI) Top Compensated Officers

Chief Executive Officer, President and Non-In...
Total Annual Compensation: C$489.1K
Chief Financial Officer and Chief Operating O...
Total Annual Compensation: C$404.7K
Chief Executive Officer of ProMetic BioScienc...
Total Annual Compensation: C$238.5K
Chief Medical Officer, Independent Director a...
Total Annual Compensation: C$267.6K
General Counsel and Corporate Secretary
Total Annual Compensation: C$229.2K
Compensation as of Fiscal Year 2014.

prometic life sciences inc (PLI) Key Developments

ProMetic Life Sciences Inc. Announces Data from Fibrotic Disease Trial

ProMetic Life Sciences Inc., has announced new data confirming that PBI-4050's anti-fibrotic effect demonstrated in the kidney in several different animal models was successfully reproduced in human kidney cell lines during in vitro experiments. The data summarizes the effect of PBI-4050 on Normal Human Dermal Fibroblasts and Human Epithelial Proximal Tubule Cells (HK-2) ("human kidney cells") in vitro experiments designed to simulate fibrosis. PBI-4050 was found to regulate the pro-fibrotic growth factors and the remodeling enzymes in both the NHDF and human kidney cells in the same manner as observed in animals. These results provide further support for the belief that the efficacy of PBI-4050 demonstrated in multiple preclinical models will translate into clinical benefit in patients suffering from fibrotic diseases such as idiopathic pulmonary fibrosis or chronic kidney disease associated with diabetes. ProMetic will commence a phase II clinical trial in the second half of 2015 with PBI-4050 in patients suffering from chronic kidney disease associated with diabetes.

ProMetic Life Sciences Inc. Provides Update on PBI-4050 for the Treatment of Idiopathic Pulmonary Fibrosis

ProMetic Life Sciences Inc. presented new pre-clinical data at the American Thoracic Society 2015 International Conference held in Denver, USA, on PBI-4050, its orally active anti-fibrotic drug candidate in phase II clinical trials for the treatment of IPF. In the gold standard animal model used to emulate pulmonary fibrosis in humans, PBI-4050 performed favorably compared to Nintedanib, one of the two FDA-approved products for such medical use. PBI-4050 significantly reduced the amount of tissue scarring observed in the lungs of non-treated animals. In this model, the combination of PBI-4050 and Nintedanib did not provide a synergistic superior outcome, in contrast to the previously reported synergistic and positive effect on reduction of fibrotic markers seen with the combination of PBI-4050 and Pirfenidone. The study results presented at the ATS annual conference demonstrated that the oral administration of PBI-4050 significantly reduced: histological lesions and scars in the lungs, inflammatory /profibrotic cytokines (TGF-1, CTGF, MCP-1, IL-23p19 & IL-6), fibrotic markers (collagen 1, iNOS & fibronectin), remodeling markers (LOX, MMP13, PAI-1, TIMP3 & ILK), growth factors expression (VEGFA, EGF, PDGF, TGF-2, EDN1).

ProMetic Life Sciences Signs Emergent Plant in Winnipeg to Process Plasma

ProMetic Life Sciences Inc. announced that it has a new 15-year agreement for a Winnipeg manufacturing plant to process medical plasma using the company's proprietary purification method. The work will be done at a Emergent BioSolutions facility with the capacity to process up to 250,000 litres of plasma annually.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PLI:CN C$2.22 CAD +0.02

PLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PLI.
View Industry Companies
 

Industry Analysis

PLI

Industry Average

Valuation PLI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 64.1x
Price/Book 20.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 63.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROMETIC LIFE SCIENCES INC, please visit www.prometic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.